drugset / Trial / NCT06554288
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
Phase 1
Recruiting
40 enrolled
Children's Mercy Hospital Kansas City
University of Kansas Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
Timeline
- Start
- 2024-10-15
- Primary completion
- 2029-11-30
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trihexyphenidyl | Small molecule | 0.25 mg/kg | — |